Evidence map›Paper›PMID 34767592›Full record

ArticlePloS one2021

Biotinylation as a tool to enhance the uptake of small molecules in Gram-negative bacteria.

Ankit Pandeya, Ling Yang, Olaniyi Alegun, Chamikara Karunasena, Chad Risko, Zhenyu Li, Yinan Wei

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ankit PandeyaDepartment of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY, United States of America.ORCID 0000-0002-7433-3129
Ling YangDepartment of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY, United States of America.
Olaniyi AlegunDepartment of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY, United States of America.
Chamikara KarunasenaDepartment of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY, United States of America.ORCID 0000-0002-0631-9034
Chad RiskoDepartment of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY, United States of America.
Zhenyu LiSaha Cardiovascular Research Center, College of Medicine, University of Kentucky, Lexington, KY, United States of America.
Yinan WeiDepartment of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY, United States of America.ORCID 0000-0002-9936-7149
University of Kentucky · US

Funding

Heart-platelet crosstalk: JNK, AF, and thrombogenesisR01HL146744 · NHLBI · RUSH UNIVERSITY MEDICAL CENTER · PI Xun Ai, Yuchi Han · 2019 to 2026
$3.2M
Inflammasome Activation Triggers Systemic Coagulation in SepsisR01HL142640 · NHLBI · UNIVERSITY OF KENTUCKY · PI LI, ZHENYU, WEI, YINAN · 2019 to 2022
$1.7M
A novel mechanism of immunosuppression in sepsis: Depletion of monocytes and macrophagesR01GM132443 · NIGMS · UNIVERSITY OF KENTUCKY · PI LI, ZHENYU, WEI, YINAN · 2019 to 2022
$1.7M
Rules for penetrating the Gram-negative bacterial envelopeR56AI137020 · NIAID · UNIVERSITY OF KENTUCKY · PI WEI, YINAN · 2018 to 2018
$565k
Inhibition of GSDMD as a new treatment for infectionR21AI142063 · NIAID · UNIVERSITY OF KENTUCKY · PI WEI, YINAN · 2019 to 2020
$405k
NHLBI NIH HHS R01 HL142640NHLBI NIH HHS R01 HL146744NIAID NIH HHS R21 AI142063NIAID NIH HHS R56 AI137020NIGMS NIH HHS R01 GM132443
6 · The paper itself

Abstract

Antibiotic resistance is a major public health concern. The shrinking selection of effective antibiotics and lack of new development is making the situation worse. Gram-negative bacteria more specifically pose serious threat because of their double layered cell envelope and effective efflux systems, which is a challenge for drugs to penetrate. One promising approach to breach this barrier is the "Trojan horse strategy". In this technique, an antibiotic molecule is conjugated with a nutrient molecule that helps the antibiotic to enter the cell through dedicated transporters for the nutrient. Here, we explored the approach using biotin conjugation with a florescent molecule Atto565 to determine if biotinylation enhances accumulation. Biotin is an essential vitamin for bacteria and is obtained through either synthesis or uptake from the environment. We found that biotinylation enhanced accumulation of Atto565 in E. coli. However, the enhancement did not seem to be due to uptake through biotin transporters since the presence of free biotin had no observable impact on accumulation. Accumulated compound was mostly in the periplasm, as determined by cell fractionation studies. This was further confirmed through the observation that expression of streptavidin in the periplasm specifically enhanced the accumulation of biotinylated Atto565. This enhancement was not observed when streptavidin was expressed in the cytoplasm indicating no significant distribution of the compound inside the cytoplasm. Using gene knockout strains, plasmid complementation and mutagenesis studies we demonstrated that biotinylation made the compound a better passenger through OmpC, an outer membrane porin. Density functional theory (DFT)-based evaluation of the three-dimensional geometries showed that biotinylation did not directly stabilize the conformation of the compound to make it favorable for the entry through a pore. Further studies including molecular dynamics simulations are necessary to determine the possible mechanisms of enhanced accumulation of the biotinylated Atto565.

Indexed as

BiotinBiotinylationEscherichia coliAnti-Bacterial AgentsBiological TransportEscherichia coli ProteinsGram-Negative BacteriaPeriplasmStreptavidinAnti-Bacterial AgentsBiotinEscherichia coli ProteinsStreptavidin

Identifiers

PMID34767592
PMCPMC8589159
OpenAlexW3212018020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.